Variations in the DHRS1 gene, which is crucial for the metabolism of retinoids, may alter the pharmacokinetics and efficacy of retinoid-derived drugs such as isotretinoin and tretinoin. These changes can affect drug levels in the body, influencing both therapeutic outcomes and toxicity risks.